lol my typing a bit scrambled on my previous post on PRR. The stock has retraced a bit but is now building again. Dendreon approval came through and the hype washed off onto Prima Biomed PRR. This stock has potential as orphan status approval pending in Europe and result likely to be known first week in June and USA FDA orphan status approval even more important is also pending. Orphan status amongst other things extends the life of the patent.
CRC may improve today following quarterly ann.
- Forums
- ASX - Day Trading
- daytrades april 30 morning ...
daytrades april 30 morning ..., page-77
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost